202
Participants
Start Date
April 14, 2010
Primary Completion Date
June 6, 2012
Study Completion Date
July 23, 2025
Riociguat (Adempas, BAY63-2521)
up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
Riociguat (Adempas, BAY63-2521)
up to 1 mg three times a day (increasing from 0.5 to 1 mg)
Riociguat (Adempas, BAY63-2521)
fixed 0.5 mg three times a day
Placebo
Placebo three times a day
Brussels
Vienna
Geneva
Sydney
Leuven
Melbourne
Herston
Innsbruck
Lugano
Palma
Zurich
Aarhus N
Ghent
Aalst
Prague
A Coruña
Greifswald
Baltimore
Falls Church
Pavia
Madrid
Majadahonda
Murcia
Toulouse
Miami
Pessac
Nantes
Fairfield
Cincinnati
Valencia
Cologne
Iowa City
Milwaukee
Rochester
Lille
St Louis
Heidelberg
Bron
Rouen
Olomouc
Naples
Augsburg
Torrance
San Diego
Westminster
Erfurt
Beijing
Singapore
Singapore
Shanghai
Shanghai
Singapore
Los Angeles
Boston
Edmonton
Vancouver
Montreal
Québec
Brno
Prague
Nagoya
Seto
Ōgaki
Higashiibaraki
Tsu
Sendai
Kita-ku, Osaka
Osaka
Suita
Kusatsu
Sunto
Arakawa-ku
Shinjuku-ku
Tanabe
Amsterdam
Amsterdam
Nijmegen
Bydgoszcz
Gdansk
Warsaw
Barcelona
Cambridge
London
Lead Sponsor
Bayer
INDUSTRY